Engineering Medicines To Improve Patient Care Pipeline Developing Best-In-Class Solutions for Patients Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Our pipeline represents a patient-centric model of innovation, which leverages proven biology and technology to efficiently allocate research and development resources, while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus. VRDN-001 Viridian’s lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). In preclinical studies, VRDN-001 was shown to be a full antagonist of IGF-1R, with more complete receptor blockade than other anti-IGF-1R antibodies, including the only currently approved TED therapy. Data from the initial dose cohorts of the Phase 2 portion of the ongoing trial established clinical proof-of-concept for VRDN-001 in patients with active TED. Preliminary data from the ongoing trial showed treatment with VRDN-001 led to reductions in proptosis, clinical activity score (CAS), and diplopia resolution. VRDN-001 was generally safe and well tolerated in the trial. The Company recently initiated its THRIVE Phase 3 trial in patients with active TED to support global marketing registration. VRDN-001 is also being evaluated in Phase 2 trial cohorts in patients with chronic TED. Pending positive results, the Company plans to start its THRIVE-2 Phase 3 trial in patients with chronic TED. Scientific publications for VRDN-001 can be found here. VRDN-001 is an investigational therapy not approved for any use in any country. VRDN-002 VRDN-002 is a distinct IGF-1R monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low volume, subcutaneous injection for the treatment of TED. Phase 1 data of VRDN-002 demonstrated an extended half-life up to 43 days. Scientific publications for VRDN-002 can be found here. VRDN-002 is an investigational therapy not approved for any use in any country. VRDN-003 VRDN-003 is a monoclonal antibody that incorporates half-life extension technology into the sequence of VRDN-001, preserving the unique pharmacological attributes of VRDN-001 while adding the enhanced pharmacokinetics of VRDN-002. VRDN-003 is designed to support administration as a convenient, low volume, subcutaneous injection for the treatment of TED, and is in development as an alternative to VRDN-002. VRDN-003 is an investigational therapy not approved for any use in any country. VRDN-004 VRDN-004 is a discovery-stage therapeutic antibody program for an undisclosed rare disease. We believe there is a significant opportunity to provide a more convenient, better performing product versus the only approved therapeutic in this disease. We are currently evaluating lead molecules generated by our antibody discovery and engineering platform. VRDN-005 VRDN-005 is a preclinical program for an undisclosed autoimmune disease indication in which we believe patient care can be advanced with a new therapeutic monoclonal antibody. VRDN-006 VRDN-006 is a preclinical program for an undisclosed autoimmune disease indication in which we believe patient care can be advanced with a new therapeutic monoclonal antibody. Read about our approach to discovering and developing potential best-in-class medicines for patients with serious and rare diseases here.